ThisPre-madeoptionalinducIBLelentiviralparticles expressesthemutant humantarget,KRAS(G12V): Kirstenratsarcomaviraloncogenehomolog (alternativename:C-K-RAS;CFC2;K-RAS2A;K-RAS2B;K-RAS4A;K-RAS4B;KI-RAS;KRAS1;KRAS2;NS;NS3;RASK2 ). ThislentivirusexpressthemutantversionofKRAS(withmutationsiteatG12V)withaN-terminalHAtag.Theexpressedproteinsequenceislistedasfollows:
m-ypydvpdya-teyklvvvgaVgvgksaltiqliqnhfvdeydptiedsyrkqvvidgetclldildtagqeeysamrdqymrtgegflcvf
ainntksfedihhyreqikrvkdsedvpmvlvgnkcdlpsrtvdtkqaqdlarsygipfietsaktrqgvddafytlvreir
khkekmskdgkkkkkksktkcvim*
(Note:YellowhighlightedistheHAtag,thered“V”isthemutationsite.)
ThemutantKRAS(G12V)isexpressedunderanoptionalinducible suCMVpromoter. Thislentiviruscan beusedforregularconstitutivehighexpression(withoutanyinduction)orusedfor inducibleexpression withtetracyclineorDoxinductionwhenthetetracyclinerepressorprotein(TetR)ispresent.
AGFP-Puromycin fusiondualMarkerundertheRSVpromoterallowsfluorescencesortingorblasticidinresistanceselectionof transducedcells. TheRFPsignaladditionallyprovidesconvenient,real-timemonitoringoftheparticles’performance.(seerelatedproducts:CAT#:LVP799andLVP762)
EachLentivirusisvalidatedonlot-by-lotbasis, andtargetexpressionisguaranteed. SeeProductManualfordetails(.pdf).
Amount:200ul,at1x107IFU/mlin DMEMmediumwith10%FBSand10xofpolybrene(60ug/ml).(Note:Whenspecificallyrequested,theconcentratedparticlescanbeprovided at1x108IFU/mlin200ulPBSsolutionfor$650.00USD).
Cat#:LVP799-GP
